title: Nintedanib in the treatment of idiopathic pulmonary fibrosis.
abstract: Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease that occurs in older adults. The clinical course of IPF is variable and hard to predict in an individual patient. Nintedanib is a tyrosine kinase inhibitor that has recently been approved in the US and European Union for the treatment of IPF. Preclinical studies have shown that nintedanib interferes with processes active in fibrosis such as fibroblast proliferation, migration and differentiation and the secretion of extracellular matrix. The safety and efficacy of nintedanib have been investigated in the phase II TOMORROW trial and in two replicate 52-week randomized, placebo-controlled phase III trials known as the INPULSIS trials. These trials demonstrated that nintedanib slowed disease progression by reducing the annual rate of decline in forced vital capacity, with a manageable side-effect profile. In this review, we summarize key data supporting nintedanib as a treatment for patients with IPF and address key questions regarding the use of nintedanib in the clinical setting.
authors: University of Buenos Aires, Buenos Aires, Argentina.
authors: Mariano E
authors: ME
authors: Mazzei
authors: National Institute for Health Research Southampton Respiratory Biomedical Research Unit and Clinical and Experimental Sciences, University of Southampton, Southampton, UK.
authors: Luca
authors: L
authors: Richeldi
authors: University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA hal.collard@ucsf.edu.
authors: Harold R
authors: HR
authors: Collard
mesh_terms: D000328:Adult; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy*; D007211:Indoles / Q000627:therapeutic use*; D018579:Patient Selection; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors
chemical_list: D004791:Enzyme Inhibitors; D007211:Indoles; D020794:Receptor Protein-Tyrosine Kinases; C530716:nintedanib
keywords: disease progression; forced vital capacity; interstitial lung disease; safety; treatment outcome; tyrosine kinase